GW-Bodies and P-Bodies Constitute Two Separate Pools of Sequestered Non-Translating RNAs

Non-translating RNAs that have undergone active translational repression are culled from the cytoplasm into P-bodies for decapping-dependent decay or for sequestration. Organisms that use microRNA-mediated RNA silencing have an additional pathway to remove RNAs from active translation. Consequently, proteins that govern microRNA-mediated silencing, such as GW182/Gw and AGO1, are often associated with the P-bodies of higher eukaryotic organisms. Due to the presence of Gw, these structures have been referred to as GW-bodies. However, several reports have indicated that GW-bodies have different dynamics to P-bodies. Here, we use live imaging to examine GW-body and P-body dynamics in the early Drosophila melanogaster embryo. While P-bodies are present throughout early embryonic development, cytoplasmic GW-bodies only form in significant numbers at the midblastula transition. Unlike P-bodies, which are predominantly cytoplasmic, GW-bodies are present in both nuclei and the cytoplasm. RNA decapping factors such as DCP1, Me31B, and Hpat are not associated with GW-bodies, indicating that P-bodies and GW-bodies are distinct structures. Furthermore, known Gw interactors such as AGO1 and the CCR4-NOT deadenylation complex, which have been shown to be important for Gw function, are also not present in GW-bodies. Use of translational inhibitors puromycin and cycloheximide, which respectively increase or decrease cellular pools of non-translating RNAs, alter GW-body size, underscoring that GW-bodies are composed of non-translating RNAs. Taken together, these data indicate that active translational silencing most likely does not occur in GW-bodies. Instead GW-bodies most likely function as repositories for translationally silenced RNAs. Finally, inhibition of zygotic gene transcription is unable to block the formation of either P-bodies or GW-bodies in the early embryo, suggesting that these structures are composed of maternal RNAs.


Introduction
Processing body (P-body) associated RNAs constitute a subset of non-translating RNAs present in a cell [1]. These RNAs cycle actively between translating ribosomes and P-bodies, where not localize to GW-bodies, but instead localizes with the maternal RNA translation repressor Smaug. Using translation inhibitors puromycin and cycloheximide, we demonstrate the GWbodies also exist in equilibrium with actively translating pools of RNAs. Finally, blockage of zygotic gene activation using the RNA polymerase II inhibitor α-amanitin shows that these newly derived P-bodies and GW-bodies originate from maternal RNAs.

Transgenes
To generate pUASp-EGFP:Gw, the full length Gw coding sequence was PCR amplified from the pAc5.1B-EGFP-DmGW182 plasmid (Addgene; [11]) using forward and reverse primers flanked with NotI and XbaI restriction sites respectively. PCR product was digested with NotI and XbaI and ligated into pUASp [29] to generate pUASp-Gw intermediate. PCR amplified EGFP sequence from pAc5.1B-EGFP-DmGW182 with flanking NotI restriction sites was digested and ligated into NotI digested pUASp-Gw to generate pUASp-Gw:EGFP. This construct was introduced into flies using P-element transformation.

Spinning disc confocal microscopy and pharmacological treatments of embryos
Live imaging of embryos was conducted using a Yokogawa CSU10 spinning disc confocal microscope (Zeiss Observer.A1). Embryos were dechorionated in 4% bleach, washed with water, and mounted in halocarbon 27 Oil (Sigma). All live images were acquired in one minute intervals using Planapochrom 63X 1.4NA Oil objective. For pharmacological manipulations, embryos were lined up and glued to a coverslip, and desiccated for 12 to 13 minutes in a closed chamber containing drierite. Following desiccation, embryos were covered in halocarbon 700 oil (Sigma). Embryos were subsequently injected using a micromanipulator (Narishige, MN-151) with either water, 10,000 μg/mL puromycin (Santa Cruz Biotechnology), 1,000 μg/mL microbially sourced cycloheximide (Sigma), or 100 μg/mL α-amanitin (Santa Cruz Biotechnology) and imaged.

Gw-bodies form de novo in the early Drosophila embryo during cellularization
To visualize GW-body dynamics in the early embryo, we generated and expressed a UAS-Gw: EGFP transgene under the regulation of the maternal α-tubulin-GAL4VP16 driver. Gw:EGFP localization in these embryos is coincident with labeling by an antibody that recognizes the Gw protein (S1A-S1F Fig). We find that Gw:EGFP possesses two different subcellular localizations during syncytial cycle 10, localizing both to the cytoplasm as well as to foci within nuclei ( Fig  1A, S1G-S1I Fig). The observation of nuclear Gw foci was highly surprising and has not been reported previously. Cytoplasmically localized Gw proteins at cycle 10, however, are not associated in foci. As syncytial cycles progress, a modest number of cytoplasmic Gw foci begin to form up to the start of cycle 14, accompanied by a concomitant decrease of nuclear Gw foci (Fig 1A). At late cycle 14 during cellularization, prominent cytoplasmic Gw foci become present in apical sections, and nuclear foci are virtually undetectable by live imaging (Fig 1A). Interestingly, this loss of nuclear foci correlates with the increase in cytoplasmic GW-body nucleation. Altogether, these results demonstrate that GW-body formation occurs de novo during syncytial cycle 14 when maternal RNAs undergo MBT-associated clearance from the embryo.
Proteins that regulate RNA decapping such as DCP1, DCP2, Hpat, and Me31B are standard markers for P-bodies [2,36,37,38,39,40]. As Me31B has been used previously to observe P-bodies in the early embryo [28], we used an endogenous Me31B protein trap line to follow P-body dynamics during syncytial divisions. Unlike Gw, Me31B proteins exist in prominent cytoplasmic puncta at cycle 10 ( Fig 1B). Another major difference between Gw and Me31B puncta is that these Me31B puncta are not associated with nuclei ( Fig 1B). Interestingly, Me31B puncta grow modestly in size and number as syncytial cycles progress but dramatically increase in number at cycle 14 during cellularization ( Fig 1B). Thus, new P-body and GW-body formation both occur at a similar time point, suggesting that a common mechanism may regulate the formation of these structures. However, the low number of GW-bodies present prior to cellularization potentially indicates that GW-bodies and P-bodies in the early embryo are distinct structures.
Finally, we live imaged a Twin protein trap line. Twin/CCR4 encodes the catalytic subunit of the CCR4-NOT deadenylation complex [41,42]. In mammalian cells, Twin/CCR4 has been shown to localize to P-body structures [3,24]. We find that Twin localization is not focal but present uniformly throughout the cytoplasm (Fig 1C). Similar uniform, non-focal distributions of Twin have also been observed in Schneider 2 (S2) cells, suggesting that Twin/CCR4 is not a component of either P-bodies or GW-bodies either in vivo or in vitro (SAB, unpublished observation).
Previous studies of GW-bodies have suggested that the integrity of these structures alter with the cell cycle [23]. We observed a similar dynamic for nuclear GW-bodies during syncytial cycles. Syncytial nuclei undergo a modified, rapid cell cycle that alternates between mitosis and S phase with no G1 or G2 phase. We find that nuclear GW-bodies form and disintegrate as nuclei exit and enter mitosis (Fig 2A). P-body structures, on the other hand, are stable throughout the syncytial cell cycle ( Fig 2B). Thus nuclear GW-bodies have a dynamic that is distinct from P-bodies.

GW-bodies are compositionally distinct from P-bodies
As Gw and Me31B positive foci are both present at cellularization, we investigated the distribution of GW-and P-body associated proteins at this stage. Gw has been shown to function in miRNA-mediated translational silencing in both mammalian and Drosophila cells [19,21,22]. We find that components of the RNA-induced silencing complex (RISC) such as Gw, AGO1, and AGO2 are present as cytoplasmic foci (Fig 3A-3C). These foci are not asymmetrically enriched in either an apical-basal or planar fashion. While nuclear GW-body foci are not detectable in live imaging experiments during cellularization, we were able to observe such foci using an anti-Gw antibody ( Fig 3A). This immunohistochemical observation also indicates that nuclear Gw foci visualized by live imaging are not a consequence of protein overexpression. We find that P-body associated proteins such as DCP1, Me31B, and Hpat also exist as puncta that are distributed throughout the cell (Fig 3D-3F). However, proteins that function in regulating deadenylation are not uniformly localized. While foci containing RISC and decapping proteins are distributed throughout the cytoplasm, Not1 and Twin are both enriched around nuclei. Not1 is largely present apically, but also forms large foci basal to the nuclei ( Fig 3G). Twin, however, is primarily enriched in the apical cytoplasm ( Fig 3H). These two distinct localizations are highly surprising considering that Not1 and Twin function in a common deadenlyation complex and suggest that Not1 and Twin potentially exist in separate cellular structures. To test this directly we double labeled embryos for Twin and Not1. In apical sections where both proteins are enriched, Twin and Not1 foci do not co-localize (S2A- S2C  Fig). We also find that large, basally located Not1 foci are adjacent to actin bundles (S2D- S2F  Fig). Currently the function of these basal actin bundles is unknown. As Not1 and Twin function in the same protein complex, the lack of colocalization between Twin and Not1 suggests that the associations between these proteins are either transient or that Twin and Not1 function in several distinct complexes or that their interactions occur outside of foci. Altogether, we find that P-body components are present as foci during late syncytial cycles and cellularization. Since GW-bodies in higher eukaryotes have been proposed to be analogous to P-bodies, one possibility is that Gw proteins associate with P-bodies during late syncytial cycles and cellularization. To determine if Gw foci observed during cellularization are P-bodies, we double labeled embryos with Gw and DCP1. We find that Gw and DCP1 did not colocalize, suggesting that GW-bodies and P-bodies exist as separate structures in the early embryo (Fig 4A-4C and 4P). We also find that DCP1 foci did not colocalize either with AGO1:GFP expressed from a protein trap line or with Twin (Fig 4D-4I and 4P). These data indicate that key components of miRISC are not present in P-bodies in vivo. The lack of association between Twin and DCP1 is consistent with our live imaging data. However, as expected, DCP1 does colocalize with decapping regulators such as Me31B and Hpat (Fig 4J-4O and 4P). Thus Drosophila P-bodies in vivo resemble P-bodies observed in yeast, which are typically composed of RNA decay factors.
As Gw does not colocalize with the standard P-body marker DCP1, we wanted to determine if Gw associated with members of the miRISC complex. Unlike observations made in other experimental contexts [11,18], we find that AGO1 does not colocalize with Gw ( Fig 5A-5C and 5P). The Gw protein has also been shown to physically interact with both Not1 and CCR4/ Twin in mammalian and Drosophila cells [14,15,16]. We find, using double labelings of Gw with Not1 or Twin:GFP, that these proteins also do not localize to Gw foci in the early embryo ( Fig 5D-5I and 5P). Furthermore, decapping proteins Me31B and HPat also do not colocalize with Gw (Fig 5J-5O and 5P). Altogether, these data suggest that GW-bodies in Drosophila embryos do not share a similar composition to P-bodies.

Analysis of developmental RNA binding proteins
As AGO1 and deadenylation complex proteins do not localize to either GW-bodies or P-bodies, we next investigated whether these proteins associate with RNA binding proteins known to direct early embryonic development. The RNA binding protein Smaug (Smg), which represses and destabilizes maternal RNAs during early embryonic development [33,43,44], has been shown to bind AGO1, Not1, Twin/CCR4, and Me31B [45,46]. Smg is present in large, cytoplasmic foci, typically in close proximity to nuclei [47]. Presumably, these Smg foci represent sites of translationally repressed maternal RNA. We find that Smg foci present during cellularization colocalize with the miRISC complex protein AGO1, as revealed by immunofluorescent staining with an AGO1:GFP protein trap line (Fig 6A-6C and 6P). Gw has been shown to physically interact with AGO1 in Drosophila cell culture [11]; however, we do not observe colocalization between AGO1 and Gw, suggesting that Smg structures also do not contain Gw proteins and that these particles are distinct. Smg particles also do not colocalize with deadenylation complex proteins Not1 and Twin (Fig 6D-6I and 6P). Previous analysis of Smg foci indicated that Smg only partially colocalizes with DCP1 during early embryonic development [47]. Likewise we find that Me31B and HPat also do not colocalize with Smg foci, indicating that Smg foci are unlike P-bodies (Fig 6J-6O and 6P). Thus, while Smg biochemically interacts with many decapping and deadenylation proteins, none of these appear to localize to Smg foci. Early fly embryos also possess RNA-bound particles associated with the Vasa protein. While the Vasa mRNA transcript is uniformly present throughout the embryo, Vasa protein is predominantly expressed in the posterior of the embryo and is highly enriched in the pole plasm [48]. We examined Vasa granules located outside of the pole plasm and observed that RISC, deadenylase, and decapping complex components do not colocalize with Vasa protein (Fig 7A-7P).
In conclusion, our colocalization analysis suggests that the early fly embryo possesses several distinct RNA foci. In addition to P-bodies and GW-bodies, early embryos also contain separate foci that contain Smg/AGO1, Twin, or Not1. All of these granules are also distinct from RNA transport granules that contain the Vasa protein.
GW-bodies constitute a separate pool of non-translating mRNAs P-body size is dependent on the size of the pool of non-translating RNAs [2]. Puromycin, which inhibits protein translation through the premature release of translating RNAs from the ribosome, increases the pool of non-translating RNAs and leads to an enlargement of P-bodies [8,25]. To test if Gw proteins respond to puromycin, we injected Drosophila embryos expressing Gw:EGFP either at the presyncytial blastoderm stage (when no GW-bodies are present) or at cellularization and observed GW-body dynamics over a twenty-minute time course. Injection of puromycin into presyncytial blastoderm embryos failed to induce GW-bodies ( Fig 8A). Thus, increasing the pool of non-translating RNAs is not sufficient to induce GW-bodies at this stage. However, injection of puromycin into cellularizing embryos causes GW-body enlargement ( Fig  8B). These data indicate that GW-bodies are composed of non-translating mRNAs. The failure of puromycin to induce GW-bodies in presyncytial blastoderm embryos suggests that the translation repression mechanism required to regulate sequestration of RNAs into GW-bodies may not be active at this stage. Potentially, this would mean that the microRNA-mediated RNA silencing pathway is not active prior to cellularization. We next tested if P-bodies labeled with Me31B:GFP respond to puromycin injection. We find that puromycin injection increases P-body size during both presyncytial blastoderm and cellularization stages of development (Fig 8C and  8D). Hence, the size of P-bodies and GW-bodies are both dependent on non-translating mRNAs. Finally, we injected puromycin into embryos expressing Twin:GFP. As Twin/CCR4 is a known component of P-bodies in mammalian cells, injection of puromycin should induce the incorporation of Twin into punctate structures. However, we find that puromycin is unable to drive Twin:GFP into P-bodies at either developmental stage (Fig 8E and 8F).
Cycloheximide inhibits translation elongation and consequently traps RNAs in polysomes. This sequestration of RNAs leads to a depletion of non-translating RNAs and consequently to the rapid loss of P-bodies [2,3,24,25]. We injected Me31B:GFP expressing presyncytial blastoderm embryos with cycloheximide and found that P-bodies present at this time point are resistant to cycloheximide (Fig 8C). Thus P-bodies present during early embryogenesis are similar to cycloheximide resistant P-bodies that form in the oocyte during oogenesis [27]. This would be consistent with P-bodies at this stage serving as sites of RNA storage. P-bodies that form during the MBT, however, are not resistant to cycloheximide (Fig 8D). Me31B, which is initially found in discrete cytoplasmic foci during cellularization, redistributes within ten minutes throughout the cytoplasm (Fig 8D). Finally, we injected cycloheximide into Gw:EGFP expressing embryos and found that GW-bodies present at cellularization also disintegrate ( Fig  8B). Thus GW-bodies, like P-bodies, are composed of non-translating RNAs.
New GW-bodies and P-bodies that form at the MBT are derived from maternal RNA The activation of zygotic transcription is one of the major hallmarks of the MBT. To determine if new transcription is required for the formation of P-bodies and GW-bodies at the MBT, we injected embryos with the RNA polymerase II inhibitor α-amanitin. We find that disruption of zygotic transcription is unable to block the formation of GW-bodies ( Fig 9B). α-amanitin treatment causes GW-bodies to form basally to the nucleus, indicating that zygotic transcription is required to establish proper GW-body distribution (Fig 9B). New P-bodies also form normally when zygotic transcription is blocked (Fig 9D). While capable of forming apically to nuclei, Pbodies that form in the absence of active zygotic transcription appear larger in size (Fig 9D). Altogether, these data indicate that newly formed P-bodies and GW-bodies at the MBT are derived from maternal RNA.

GW-bodies and P-bodies have different dynamics and distributions in the early Drosophila embryo
Our in vivo live imaging analysis of GW-bodies and P-bodies indicates that these structures have different spatial and temporal dynamics. While cytoplasmic GW-bodies are mostly absent during early cortical syncytial cycles, P-bodies are present throughout early embryonic development. This is consistent with previous reports that described P-body structures during oogenesis and early embryonic development [27,28]. Here we show that GW-bodies are also present, but localize initially in the nucleus. These nuclear GW-bodies are detectable using live imaging as well as by immunohistochemistry. Consistent with this nuclear localization is the presence of a nuclear localization signal in the Gw sequence [13]. Interestingly, nuclear GW-bodies are depleted as cytoplasmic GW-bodies increase in number, indicating that these two populations of GW-bodies may exist in equilibrium. Similar observations have been made for the P-body component LSm-4, which localizes to Cajal bodies under conditions that limit P-body nucleation [49]. As Gw has been shown to colocalize with LSm-4 in S2 cells [12], one possibility is that nuclear GW-bodies may also overlap with Cajal bodies. The LSm2-8 complex, which functions in RNA splicing within the nucleus, has been shown to be a component of Cajal bodies [50]. Thus, Gw proteins may potentially interact with shared components between the cytoplasmic LSm1-7 complex and the nuclear LSm2-8 complex. Interestingly, Cajal bodies also disassemble and reassemble with the cell cycle [51]. We observed that nuclear GW-bodies form and disintegrate with the cell cycle as well, similar to previous observations of cytoplasmic GW-bodies in mammalian cells [23]. P- bodies, however, are extremely stable during the cortical syncytial cycles, thus further highlighting the differences in dynamics between both structures.

GW-bodies are distinct from P-bodies
Previous analyses conducted in cell culture indicate that GW-bodies share many of the proteins associated with P-bodies, including DCP1, XRN1 and LSm-4 [10,11,12]. In this report, we conducted an in vivo analysis of GW-body constituents using immunohistochemical labelings of endogenous proteins and found that GW-bodies are not associated with typical P-body markers such as DCP1, Me31B, Hpat, Twin, and Not1. Unfortunately, we were unable to determine the presence or absence of LSm proteins to GW-bodies due to the lack of an available antibody. Furthermore, the miRISC component AGO1 was also not observed in Gw foci in vivo. Thus, we find that GW-body structures observed in the early embryo differ markedly from those observed in cell culture. These discrepancies may be due to differences in experimental approach. Localization experiments conducted in Drosophila S2 cells, which have previously established the existence of a common structure, relied on co-overexpression of Gw with either DCP1, XRN1, LSm-4, or AGO1, [11,12]. Thus, these observations potentially may not reflect endogenous localizations. In fact, co-expression of Gw and AGO1 both in vivo and in vitro has been shown to induce the recruitment of AGO1 to GW-bodies [11,18]. Potentially these cooverexpression studies reveal transient associations between these proteins and GW-bodies. Our analyses of endogenous proteins indicate that GW-bodies are unique in their composition with regard to P-body or RISC components.
The Gw protein, however, has been shown to physically bind to decapping and deadenylation proteins [11,14,15,16,52]. More importantly, functional assays have implicated decapping and deadenylation downstream of Gw. RNA tethering assays that physically link Gw to RNA reporter constructs demonstrate that Gw promotes RNA decay and translational silencing in both Drosophila S2 cells and in a heterologous yeast model [11,53]. Notably, these assays reveal that inhibition of decapping or deadenylation using RNA knockdown suppresses Gw-dependent RNA decay without affecting translational silencing [11,16]. We find that neither deadenylation regulators nor decapping factors localize to Gw-bodies in vivo, suggesting that GWbodies are not sites of RNA decay. Thus, the RNA metabolic functions associated with Gw may occur outside of GW-bodies themselves. Recently, decapping, deadenylation, and AGO1/Gw proteins have been localized to actively translating ribosomes [54]. Therefore, polysomes may potentially serve as alternative sites for RNA decay. Potentially, GW-bodies may exist only as sites of sequestered non-translating RNAs. We also find that Smg foci do not colocalize with components of the CCR4-Not deadenylation complex or with decapping factors, despite the biochemical associations between Smg and these proteins. Thus translationally repressed, sequestered RNAs may not associate in general with decapping or deadenylation effectors.
Despite compositional differences, both Gw-bodies and P-bodies are similar in that they exist in equilibrium with actively translating pools of RNAs. We find that artificially increasing the pool of non-translating RNAs using puromycin injection enhances the size of both P-bodies and GW- bodies. Thus GW-bodies, like P-bodies, represent a variety of non-translating RNAs. However, the release of RNAs from polysomes is not sufficient to induce GW-body formation during the presyncytial blastoderm stage of development. Several explanations can account for this failure to incorporate Gw into Gw-bodies. One possibility is that the Gw protein at this stage may not be associated with RNA. Another possibility is that a critical factor required for the incorporation of Gw into GW-bodies is missing from embryos at this stage or that the presyncytial embryo might express a repressor that blocks GW-body formation. Potentially, the translation inhibition mechanism that induces GW-body formation or an appropriate RNA substrate may be absent.
Drosophila P-bodies are enriched for decapping factors P-bodies have been proposed to act as sites of RNA decay and are associated with various forms of RNA turnover including 5'-3' exonucleolytic decay and nonsense mediated decay [2,3,6,55]. In yeast, P-bodies are associated with the 5'-3' exonuclease XRN1 as well as decapping factors DCP1 and DCP2 and decapping regulators Pat1/Hpat, Dhh1/Me31B, and the LSm1-7 complex [2]. In addition to these regulators of decapping and degradation, proteins that are functionally implicated in deadenylation also localize to P-body structures. CCR4, which serves as the catalytic component of the CCR4-NOT deadenylation complex, is weakly present in yeast P-bodies [2]. The association between CCR4 and P-bodies has been shown to increase upon stress signaling induced by glucose withdrawal [56]. On the other hand, the localization of Not1 to P-bodies has only been shown under conditions of impaired decapping [57]. Such observations suggest that deadenylation proteins only transiently associate with Pbodies in yeast. P-bodies in higher eukaryotes, however, are more heterogenous in their protein composition. Components that regulate deadenylation such as CCR4/Twin appear to be constitutive components of P-bodies in higher organisms [3,24]. Furthermore, other components such as regulators of the miRNA pathway, including the argonaute proteins and Gw/GW182, have been shown to localize to P-body-like structures [10,17,21]. Our analysis of P-bodies in Drosophila embryos suggests that these structures are enriched primarily for decapping factors. Unlike Pbodies observed in mammalian cells, neither deadenylation complex factors nor miRNA regulators localize to DCP1 foci. These data are consistent for a role for P-bodies in RNA destabilization via decapping. Indeed, P-bodies that form at the midblastula transition appear to be important for the destabilization of maternal RNAs such as bicoid, oskar, and twine [27,58]. Interestingly, we were not able to induce the recruitment of Twin to P-bodies using puromycin treatment. These results indicate that deadenylation potentially occurs outside of these structures. Another possibility is that components that regulate deadenylation only incorporate into P-bodies upon stress. This is in line with many observations that have implicated environmental stress in the regulation of P-body size and number. In unicellular organisms such as budding yeast, changes in nutrient availability, osmotic pressure, ultraviolet light exposure, or low pH trigger mobilization of translating RNAs into P-bodies [1,59]. Similar roles for P-bodies have also been observed in multicellular organisms. Oogenesis in Drosophila is regulated by nutrient availability, and starvation of female flies induces a mid-oogenesis checkpoint that leads to the degradation of late stage egg chambers and an arresting of pre-vitellogenic egg chambers [60,61]. This nutrient withdrawal induces P-body formation in arrested nurse cells, which appears to be critical for maintaining oocyte viability [62]. Thus in vivo, P-body formation is also associated with RNA storage during stress-induced cellular quiescence. Movement of RNAs into P-bodies appears to play a protective function in yeast as well as cells carrying deletion mutations in either LSm1, Pat1 or Dhh1, all of which encode core P-body components, lose viability when subcultured following prolonged nutrient deprivation [63,64]. Potentially stress signaling pathways may be required for the recruitment of deadenylation factors into P-bodies.

New GW-bodies and P-bodies form at the midblastula transition
The importance of Gw at the MBT has previously been documented as gw mutant embryos arrest at this stage and fail to undergo cellularization [12]. Interestingly, both GW-bodies and P-bodies form in large numbers during cellularization. However, inhibition of transcription at the MBT using α-amanitin indicates that zygotic gene activation is not required for the formation of new P-bodies and GW-bodies. Therefore, these new GW-bodies and P-bodies are most likely derived from maternal RNAs. This is consistent with previous reports that indicate that P-bodies play an important role in maternal RNA turnover at the MBT [58]. However, the mechanism that governs the formation of GW-bodies at this stage remains a mystery. In Drosophila, miR-309 cluster is zygotically expressed at the MBT to promote maternal RNA turnover [65]. As Gw plays a major functional role in miRNA-mediated gene silencing, we expected that α-amanitin treatment would inhibit miRNA dependent degradation of maternal RNA and that we would observe a concomitant effect of GW-body formation. Knockout of zygotic transcription, however, causes no effect on GW-body formation. Thus, nucleation of GW-bodies during the MBT is potentially not dependent on zygotic miRNA expression. The enlargement of P-bodies after the inhibition of zygotic gene activation suggests that efficient turnover of maternal RNAs may be compromised. This may reflect a loss of miR-309 cluster expression. GW-bodies, on the other hand, may form to shield a subset maternal RNAs from MBT-associated degradation.

Conclusion
Altogether, these data indicate that GW-bodies and P-bodies represent two separate pools of non-translating RNAs. GW-bodies have a different spatial-temporal regulation, biochemical composition, and subcellular distribution mechanism to P-bodies. Future characterizations of the RNA contents of GW-bodies will provide valuable insights into the functional role of these structures. Furthermore, identification of RNAs present in GW-bodies may disclose RNAs important for regulating developmental processes such as cellularization. antibodies. Stocks obtained from the Bloomington Drosophila Stock Center (NIH P40OD018537) were used in this study.